Document is current

Any future updates will be listed below

First-in-class topical therapeutic omilancor ameliorates disease severity and inflammation through activation of LANCL2 pathway in psoriasis

Crossref DOI link: https://doi.org/10.1038/s41598-021-99349-y

Published Online: 2021-10-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark